Human Anti-ERBB2 Recombinant Antibody (clone E401) (CAT#: FAMAB-0542WJ)

Figure 1 ErbB-2 expression on cultured cells (A) and cytolytic activities of MoAbs CH401, E401, E907, and chHA58 (B).

A, Cultured cells were incubated for 2 h at 4°C with ¹²⁵I-labeled MoAbs. Following washing, bound radioactivity of cells was counted in a γcounter. B, Cells were incubated with MoAbs. Aliquots of cells were removed at 48 h and viable cells were determined by trypan blue staining. The percentage cell survival was calculated as (the viable cell number/non-treated cell number per milliliter)×100. Data are shown as the mean value±SD of three independent experiments. All the ErbB-2-positive cells were susceptible to cytolytic activity of MoAb CH401 or E401, while the ErbB-2-negative cells were not. ■MoAb CH401, MoAb E401, MoAb E907, □chHA58.

Sasaki, S., Tsujisaki, M., Jinnohara, T., Ishida, T., Sekiya, M., Adachi, M., ... & Imai, K. (1998). Human tumor growth suppression by apoptosis induced with anti‐ErbB‐2 chimeric monoclonal antibody. Japanese journal of cancer research, 89(5), 562-570.

Figure 2 Internalization of anti-ErbB-2 MoAb (A) and down-modulation of ErbB-2 receptors by anti-ErbB-2 MoAbs (B).

A, Uptake of ¹²⁵I-labeled MoAb CH401 (○) , E401 (●) or E907 (□) into SV22 cells was measured at 37°C. The percentage internalization of the MoAbs was evaluated after pH 2.8 desorption by subtracting the background uptake at 0°C. B, Down-regulation of cell surface ErbB2 protein by MoAb CH401 (○) , E401 (●) or E907 (□) was investigated. The percentage modulation was calculated by dividing the cpm of the binding of MoAb E919 at the indicated time by the total cpm initially bound to the cell surface. (Anti-ErbB-2 MoAb E919 recognizes an epitope distinct from those of MoAbs CH401, E401 and E907.)

Sasaki, S., Tsujisaki, M., Jinnohara, T., Ishida, T., Sekiya, M., Adachi, M., ... & Imai, K. (1998). Human tumor growth suppression by apoptosis induced with anti‐ErbB‐2 chimeric monoclonal antibody. Japanese journal of cancer research, 89(5), 562-570.